62,809 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Jump Financial LLC

Jump Financial LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 62,809 shares of the biopharmaceutical company's stock, valued at approximately $2,835,000. Jump Financial LLC owned about 0.08% of PTC Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in PTC Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,798,666 shares of the biopharmaceutical company's stock worth $66,743,000 after acquiring an additional 10,886 shares in the last quarter. Diversified Trust Co increased its stake in PTC Therapeutics by 10.4% during the 4th quarter. Diversified Trust Co now owns 16,818 shares of the biopharmaceutical company's stock valued at $759,000 after purchasing an additional 1,578 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of PTC Therapeutics by 8.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company's stock worth $269,000 after buying an additional 455 shares during the last quarter. KBC Group NV lifted its stake in shares of PTC Therapeutics by 36.4% during the fourth quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock worth $137,000 after buying an additional 813 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of PTC Therapeutics during the fourth quarter valued at $79,000.

PTC Therapeutics Trading Up 0.1 %

PTC Therapeutics stock traded up $0.07 during midday trading on Tuesday, reaching $48.26. 453,094 shares of the stock traded hands, compared to its average volume of 809,221. The firm has a market cap of $3.81 billion, a PE ratio of -8.11 and a beta of 0.58. The company has a 50-day simple moving average of $50.18 and a two-hundred day simple moving average of $46.32. PTC Therapeutics, Inc. has a 12-month low of $24.00 and a 12-month high of $58.38.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley reiterated an "overweight" rating and set a $70.00 price target (up previously from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. Citigroup raised their price target on shares of PTC Therapeutics from $32.00 to $45.00 and gave the stock a "sell" rating in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and issued a $65.00 price objective on shares of PTC Therapeutics in a research note on Tuesday. Scotiabank started coverage on shares of PTC Therapeutics in a report on Friday, March 7th. They issued a "sector perform" rating and a $55.00 price target on the stock. Finally, Cantor Fitzgerald lifted their price objective on PTC Therapeutics from $76.00 to $113.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, PTC Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $63.92.

Insider Activity

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 1,333 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $66,783.30. Following the sale, the vice president now owns 105,515 shares in the company, valued at $5,286,301.50. This represents a 1.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Christine Marie Utter sold 879 shares of PTC Therapeutics stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the transaction, the chief accounting officer now owns 63,442 shares of the company's stock, valued at $3,178,444.20. The trade was a 1.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,501 shares of company stock valued at $1,546,088. 5.50% of the stock is currently owned by company insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.